Hospital
Rhea Medical Center
Rhea Medical Center was paid $5.88M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoRHEA MEDICAL CENTER
DAYTON, TN 37321
DAYTON, TN 37321
33aNPI1811987084assigned 10/27/2005
33bProvider typeCritical Access Hospital
28Total paid$5.88M
24GClaims215,318
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Tennessee
Rank by total paid#1 of 15
Median peer was paid$1.48M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,422 | $819K | |
| 2019 | 39,052 | $1.01M | |
| 2020 | 30,917 | $858K | |
| 2021 | 29,733 | $905K | |
| 2022 | 28,354 | $905K | |
| 2023 | 28,641 | $789K | |
| 2024incomplete | 22,199 | $588K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 24,746 | 23,574 | $1.79M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 18,457 | 16,727 | $1.64M |
| 64493 | 5.8% | 1,291 | 1,147 | $341K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.0% | 6,454 | 5,916 | $235K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 5,269 | 5,004 | $184K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 17,912 | 15,001 | $118K |
| 64635 | 1.9% | 292 | 267 | $114K | |
| 80053 | Comprehensive metabolic panel | 1.9% | 14,840 | 13,162 | $113K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 7,932 | 7,469 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 9,091 | 7,128 | $100K |
| 64494 | 1.7% | 1,244 | 1,095 | $98K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 1,920 | 1,859 | $88K |
78 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 5,212 | $85K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.0% | 2,412 | $61K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 7,487 | $59K |
| G0378 | Hospital observation service, per hour | <1% | 1,286 | $56K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,738 | $44K |
| 99285 | Emergency room visit (most serious) | <1% | 461 | $41K |
| 64495 | <1% | 614 | $39K | |
| 27096 | <1% | 168 | $38K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,596 | $37K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,783 | $36K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,576 | $34K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,219 | $33K |
| 81001 | <1% | 9,231 | $31K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,740 | $27K |
| 64483 | <1% | 87 | $27K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 718 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,271 | $22K |
| 84484 | <1% | 1,444 | $22K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 284 | $21K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,533 | $20K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 237 | $17K |
| 20610 | <1% | 435 | $16K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 59 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 782 | $15K |
| 64451 | <1% | 49 | $14K | |
| 64636 | <1% | 172 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,650 | $11K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 731 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 847 | $7K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 26 | $6K |
| 84703 | <1% | 566 | $5K | |
| 62323 | <1% | 16 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 99 | $5K |
| 82150 | <1% | 763 | $5K | |
| 94761 | <1% | 935 | $4K | |
| 83690 | <1% | 610 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,371 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $3K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,701 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 98 | $3K |
| 80306 | <1% | 315 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,285 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 300 | $2K |
| 64490 | <1% | 14 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 423 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 707 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,364 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 325 | $2K |
| 81025 | <1% | 261 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 97 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 16 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 958 | $1K |
| 64491 | <1% | 14 | $742.80 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 179 | $733.25 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 857 | $627.76 |
| 85730 | <1% | 178 | $551.30 | |
| 96376 | <1% | 94 | $524.48 | |
| 74022 | <1% | 26 | $485.87 | |
| 74018 | <1% | 60 | $460.41 | |
| 85610 | <1% | 178 | $453.39 | |
| 81003 | <1% | 264 | $399.28 | |
| 83605 | <1% | 62 | $360.39 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 75 | $327.35 |
| 76000 | <1% | 15 | $297.80 | |
| J3490 | Unclassified drugs | <1% | 505 | $269.17 |
| 84145 | <1% | 26 | $225.18 | |
| 83735 | <1% | 59 | $195.48 | |
| 72110 | <1% | 14 | $173.98 | |
| 87040 | <1% | 20 | $162.32 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 163 | $109.58 |
| 87186 | <1% | 13 | $89.80 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 436 | $67.48 |
| 77002 | <1% | 79 | $63.72 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 147 | $28.68 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 15 | $3.93 |
| A9270 | Non-covered item or service | 0% | 4,242 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 52 | $0.00 |
| 88342 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANDERS, HARV (CFO)
| Provider | Location | Paid |
|---|---|---|
| Rhea Medical Center | Spring City, TN | $902K |
| Rhea Medical Center | Spring City, TN | $786.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.